Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program.
暂无分享，去创建一个
M. Pfeffer | S. Yusuf | A. Cohen-Solal | K. Swedberg | J. Rouleau | L. Olsson | A. Ducharme | C. Granger | E. Michelson | J. McMurray | M. Puu | A. Maggioni | James B. Young | B. Olofsson